Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
$259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing CapacityMadrigal intends to submit a new drug application for resmetirom in the first half of 2023 CONSHOHOCKEN,... | December 21, 2022
Source: marketscreener.com